These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 38896129

  • 1. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal.
    Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, Darcourt J, Comte V, Humbert O.
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3696-3708. PubMed ID: 38896129
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [Abstract] [Full Text] [Related]

  • 7. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer.
    Humbert O, Bauckneht M, Gal J, Paquet M, Chardin D, Rener D, Schiazza A, Genova C, Schiappa R, Zullo L, Rossi G, Martin N, Hugonnet F, Darcourt J, Morbelli S, Otto J.
    Eur J Nucl Med Mol Imaging; 2022 Sep 05; 49(11):3878-3891. PubMed ID: 35562529
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
    Ayati N, Lee ST, Zakavi SR, Cheng M, Lau WFE, Parakh S, Pathmaraj K, Scott AM.
    J Nucl Med; 2021 Jul 01; 62(7):926-933. PubMed ID: 33246978
    [Abstract] [Full Text] [Related]

  • 11. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer.
    Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, Zhao W, Yang Z, Li N.
    Cancer Imaging; 2024 Sep 10; 24(1):120. PubMed ID: 39256860
    [Abstract] [Full Text] [Related]

  • 12. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L.
    Clin Lung Cancer; 2021 Sep 10; 22(5):432-440. PubMed ID: 33879398
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers.
    Ito K, Kitajima K, Toriihara A, Ishibashi M, Nakahara T, Daisaki H, Ohe Y, Honda R, Kijima T, Hasegawa S, Nakajo M.
    Ann Nucl Med; 2021 Nov 10; 35(11):1253-1263. PubMed ID: 34370219
    [Abstract] [Full Text] [Related]

  • 14. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan 10; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 15. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 10; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 16. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Usmanij EA, Natroshvili T, Timmer-Bonte JNH, Oyen WJG, van der Drift MA, Bussink J, Geus-Oei LF.
    J Nucl Med; 2017 Aug 18; 58(8):1243-1248. PubMed ID: 28336778
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.